Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

Rhea-AI Summary

Verve Therapeutics, a biotechnology firm focused on innovative cardiovascular treatments, will have its CEO, Sekar Kathiresan, present at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 9:10 a.m. ET. The presentation will be available via live webcast on the company’s investor website, archived for 60 days afterward. Verve specializes in gene editing medicines, targeting genes like PCSK9 and ANGPTL3 to lower LDL cholesterol levels, aiming to transform cardiovascular disease care. Their lead candidate, VERVE-101, is in IND-enabling studies, particularly aimed at treating familial hypercholesterolemia.

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Cowen 42^nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 60 days following the presentation.

About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Gina Nugent
Ten Bridge Communications
gina@tenbridgecommunications.com

 

FAQ

What is the purpose of Verve Therapeutics' CEO presentation at the Cowen conference?

Sekar Kathiresan, CEO of Verve Therapeutics, will discuss the company's innovative cardiovascular gene editing therapies at the Cowen 42nd Annual Healthcare Conference on March 8, 2022.

What date and time is Verve Therapeutics' presentation scheduled?

The presentation by Verve Therapeutics at the Cowen conference is scheduled for March 8, 2022, at 9:10 a.m. ET.

How can I watch the Verve Therapeutics conference presentation?

You can watch the presentation live through a webcast available in the investor section of Verve Therapeutics' website, with an archive accessible for 60 days.

What are the main focuses of Verve Therapeutics' research?

Verve Therapeutics focuses on gene editing to lower LDL cholesterol, targeting genes like PCSK9 and ANGPTL3 to treat cardiovascular diseases.

What is VERVE-101 and its significance?

VERVE-101 is Verve Therapeutics' lead product candidate designed to permanently disable the PCSK9 gene to reduce LDL cholesterol levels, aimed at treating patients with familial hypercholesterolemia.